Latest HBV Stories
A novel drug developed by Gilead Sciences and tested in an animal model at the Texas Biomedical Research Institute in San Antonio suppresses hepatitis B virus infection by stimulating the immune system and inducing loss of infected cells.
Exciting new data presented today at the International Liver Congress™ 2013 include results from early in vitro and in vivo studies targeting covalently closed circular DNA (cccDNA), which may form the basis of a cure for chronic hepatitis B virus (HBV) infection.
In the first study of its kind, lay health workers increased screening rates for hepatitis B virus (HBV) and knowledge about the disease among a group of Asian Americans, known as the Hmong.
The Association of Asian Pacific Community Health Organizations (AAPCHO) received a 3-year grant totaling over $700,000 from the National Institutes of Health (NIH) to develop new Health Information
A University of Colorado Boulder-led team has discovered two prime targets of the Hepatitis B virus in liver cells, findings that could lead to treatment of liver disease in some of the 400 million people worldwide currently infected with the virus.
Singapore, Sept 6, 2012 - (ACN Newswire) - Scientists from A*STAR's Singapore Institute for Clinical Sciences (SICS), together with clinical collaborators from London(1), discovered for the first time
- A ceramic container used inside a fuel-fired kiln to protect pots from the flame.